Cirsium Biosciences的封面图片
Cirsium Biosciences

Cirsium Biosciences

生物技术研究

San Diego,CA 1,690 位关注者

Democratizing gene therapy through transformative manufacturing methods

关于我们

Democratizing gene therapy through transformative manufacturing methods

网站
https://cirsiumbio.com/
所属行业
生物技术研究
规模
11-50 人
总部
San Diego,CA
类型
私人持股

地点

Cirsium Biosciences员工

动态

  • Cirsium Biosciences转发了

    查看Jessica Mendez的档案

    Biotech | Recruiter | Human Resources | Talent Management

    Cirsium Bio is manufacturing high-quality AAV vectors for genetic medicines in plants. Join this dynamic, innovative team in San Diego! #AAV #viralvectors #opentowork #biotech #sandiegobiotech #molecularbio #cellculture #oncology #SRA #hiring #researchassociate #plantscience

  • 查看Cirsium Biosciences的组织主页

    1,690 位关注者

    Growing plants for AAV production requires precision beyond just tracking water and soil. Here are a few other key factors we optimize to ensure healthy plant growth: ?? Plant Appearance: Assessing leaf and stem condition to ensure optimal growth. ?? Plant Weight: Tracking biomass to optimize yield and efficiency. ?? Light Spectrums: Adjusting wavelengths to meet plants' specific needs and enhance production. These are just a few of the many factors we carefully monitor to keep our plants thriving for AAV production!

    • 该图片无替代文字
    • 该图片无替代文字
  • 查看Cirsium Biosciences的组织主页

    1,690 位关注者

    Stepped out of our regular "lab lane" and onto the bowling lane to celebrate Dan and Dante’s birthdays—with strikes, spares, and only a few gutter balls! ?? It turns out our team is just as fueled by good data in bowling as by good data in the lab.

    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
    • 该图片无替代文字
      +2
  • Today is Rare Disease Day—a reminder of how much work still needs to be done. Rare diseases aren’t actually rare. ?? They affect over 300 million people worldwide and 25–30 million Americans. ?? There are 7,000+ rare diseases, and 90% of them don’t have an FDA-approved treatment. And when treatments do exist? The price tags are wild. ?? Lenmeldy (gene therapy for early-onset metachromatic leukodystrophy): $4.25M for a one-time treatment. ?? Hemgenix (gene therapy for hemophilia B): $3.5M per dose. Here’s the problem: developing and manufacturing these treatments is too expensive, too slow, and full of roadblocks. And that means patients—real people—are left waiting. This is exactly why we’re working to remove cost, time, and production bottlenecks from gene therapy manufacturing. The science exists. The therapies work. Now we need to make them accessible. Today, we recognize the patients fighting for better treatments, the scientists pushing boundaries, and the advocates demanding change. Together, we keep pushing forward.

    • 该图片无替代文字
  • Next week, Pranav Mathur will be presenting at the Drug Discovery Innovation Programme (DDIP) in San Diego! He’ll be diving into our platform and addressing the topic: ?? Developing Scalable and Cost-Effective Gene Therapies to Reduce Patient Cost, and Enhance Global Outreach This discussion is crucial for addressing existing bottlenecks and our platform's solution to make gene therapies more accessible and affordable for patients worldwide. Check out the full agenda here: https://lnkd.in/e6-FGtce

    • 该图片无替代文字
  • The new year brings big changes—35,000 square feet of new production space, to be exact! We’ve been hard at work transforming this space to expand our production capabilities for both pilot and commercial scale. Here’s what’s this will allow us to do: ?? Establishing cGMP operations to scale production. ?? Expanding our platform’s reach to additional viral vectors and vector-based products. ?? Validating more AAV serotypes through head-to-head NHP studies. ??? Check out the video for a full breakdown of this new space and how we’re putting it to work!

  • There are roughly 435,000 unique land plant species on Earth—so why do we use just one to produce AAVs? ?? ?? ?? While plants like wheat or soy might be household names, Nicotiana benthamiana quietly steals the spotlight in gene therapy manufacturing. ?? ?? Click through to see why this under-the-radar plant is the MVP for AAV production.

  • Earlier this month, we had the pleasure of hosting team members from EverGlade Consulting and Aspire Financials for a site visit. Both teams have been invaluable partners in advancing our plant-based AAV manufacturing platform as we scale production. EverGlade Consulting’s expertise in navigating complex funding initiatives has been instrumental in driving our growth, while Aspire Financials’ financial guidance and support have helped ensure a strong foundation for our expansion. We’re grateful for the collaboration and excited for what’s ahead. Thank you to both teams for your tremendous support in helping us accomplish our vision!

    • 该图片无替代文字
  • ?? "What advice would you give young girls who dream of a career in science?" In celebration of the International Day of Women and Girls in Science, some of the women on our team shared their advice for the next generation of scientists. From embracing failures as part of discovery to finding mentors who inspire you, their words reflect the curiosity, resilience, and passion that drive innovation. Here’s to those paving the way for the next generation of scientists! #InternationalDayOfWomenAndGirlsInScience #February11 #Feb11

相似主页

查看职位

融资